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A B S T R A C T
Neurometabolic disorders stem from errors in metabolic processes yielding a neurological phenotype. A subset of
those disorders encompasses mitochondrial abnormalities partially due to mitochondrial DNA (mtDNA) deple-
tion. mtDNA depletion can be attributed to inheritance, spontaneous mutations or acquired from drug-related
toxicities. In the armamentarium of diagnostic procedures, mtDNA quantification is a standard for disease
classification. However, alterations in mtDNA obtained from peripheral tissues such as skin fibroblasts and blood
cells do not often reflect the severity of the affected organ, in this case, the brain. The purpose of this review is to
highlight the pitfalls of quantitating mtDNA from peripheral –and not limited to-tissues for diagnosing patients
suffering from a variety of mtDNA depletion syndromes exhibiting neurologic abnormalities. In lieu, a quali-
tative test of mitochondrial substrate-level phosphorylation –even from peripheral tissues-reflecting the ability of
mitochondria to rely on glutaminolysis in the presence of respiratory chain defects is proposed as a novel di-
agnostic assessment of mitochondrial functionality.
1. Neurometabolic disorders
Stated simply, neurometabolic disorders are those due to enzyme or
cofactor deficiencies leading to significant alterations in metabolism to
the extent of affecting the developing brain. Enzyme deficiencies may
be caused by genetic mutations inherited from the parents or acquired
during the fetal stage (Willemsen et al., 2016), (El-Hattab and Scaglia,
2013), (Suomalainen and Battersby, 2018). Even though mtDNA is
maternally inherited (see section 2) the diseases mentioned below
follow Mendelian inheritance since all mutations affect nuclear-en-
coded proteins. These disorders encompass a wide variety of conditions
including organic acidurias, amino-acidopathies (including defects of
the urea cycle), lipofuscinoses, leukodystrophies, and disorders of the
peroxisomes, lysosomes and mitochondria. In the vast majority of cases
there is no cure and treatment remains palliative, highly dependent on
the diagnostic workup of patients. To this end, “five new things” have
emerged in the literature reviewed in (Willemsen et al., 2016), speci-
fically: i) next-generation sequencing combined with next-generation
metabolic screening; ii) recognition of disease-specific MRI patterns; iii)
realization that some neurometabolic disorders do not follow a classic
autosomal recessive mode of inheritance in all families; iv) gene
therapy may soon be an option for treatment; v) neurometabolic dis-
orders also emerge in the adult life of some patients, thus future
professionals should be aware and prepared. The above “five new
things” not only shorten the time for definite diagnosis but also protect
the patients from unnecessary, often invasive procedures as well as
decreasing costs.
There are a number of mitochondrial disorders that may yield a
neurometabolic phenotype; among them, depletion of mitochondrial
DNA (mtDNA) -due to a variety of reasons, see section 4 is a potential
underlying cause which has rightfully earned own entries in the Men-
delian inheritance in Man, termed mtDNA depletion syndromes (MDS).
Before exploring this further, a background on mtDNA is warranted.
2. Mitochondrial DNA
In humans, mtDNA is a 16,589 base-pair long, double-stranded
circular DNA sequence coding for 13 polypeptides of electron transport
chain components, the 12S and 16S ribosomal RNAs and 22 transfer
RNAs critical for mitochondrial protein synthesis. Its two strands ex-
hibit different sedimentation rates due to enrichment of guanine in one
of them, thus they are referred to as “heavy” and “light” strand.
Nucleated cells harbor hundreds or thousands of mtDNA copies
(Ylikallio and Suomalainen, 2012), (Miller et al., 2003); furthermore,
mtDNA content may vary over time within the same cell (Moraes,
2001). It is a recurrent question how many mtDNA copies are present
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per mitochondrion, but it is best to consider mitochondria as a highly
dynamic intracellular network (Chan, 2006); thus, it is perhaps more
correct to report mtDNA copies per cell per some other mitochondrial
marker rather than mitochondrial count number. These copies are
bound to specific proteins forming so-called nucleoids in the shape of
foci or puncta attached to the inner mitochondrial membrane (Hensen
et al., 2014), (Spelbrink, 2010). The mtDNA/nucleoid molecule ratio in
cultured human cells is 1.4 (Kukat et al., 2011), thus, it is probably safe
to assume that one nucleoid binds to one mtDNA molecule (Johnston
et al., 2015).
In one end of the mtDNA content spectrum, the human oocyte
contains hundreds of thousands of mtDNA copies. However, following
fertilization, mtDNA replicates only after the blastocyst stage; until this
occurs, zygote mtDNA copies are being distributed to all blastocyst
cells. Consequently, each female primordial germ cell harbors a rela-
tively small number of mtDNA copies. The reduction of mtDNA copies
in the primordial germ cells is known as “bottleneck”, a phenomenon
that we now know to exist in other cell types as well, reviewed in
(Zhang et al., 2018). The number of mtDNAs transmitted through this
bottleneck in humans has been estimated to vary from ~9 (Li et al.,
2016) to ~30–35 (range 9–141) (Rebolledo-Jaramillo et al., 2014). The
time elapsed for one round of mtDNA replication is about 1 h (Clayton,
1982) and it takes place independently from cell division, obviously
also occurring in post-mitotic cells. During fetal life, mtDNA amount
increases but not appreciably (Suomalainen and Isohanni, 2010); en-
ergy provision by glycolysis is more prevalent thus, even the most se-
vere mitochondrial abnormalities do not yet manifest (Suomalainen
and Isohanni, 2010). mtDNA content as well as respiratory chain sub-
units increase dramatically in the first year of life, a period coinciding
with the manifestation of several mtDNA depletion syndromes (Morten
et al., 2007).
Up until recently it was believed that mtDNA is exclusively mater-
nally inherited; however, it was recently shown that mtDNA can also be
inherited from the father (Luo et al., 2018), although this seems to be a
very rare event, and currently contested (Lutz-Bonengel and Parson,
2019). In any case, paternal contribution of mtDNA to the fertilized egg
is expected to be negligible, because the number of mtDNA molecules in
the oocyte outnumber those in the sperm by a factor of 10,000 (Pyle
et al., 2015). Furthermore, it was postulated that the results of (Luo
et al., 2018) could be explained by the presence of multicopies of
mtDNA in the nuclear genome termed “Mega-NUMT” that segregate in
an autosomal dominant manner regardless of parental origin
(Balciuniene and Balciunas, 2019). Thus, in the vast majority –if not all-
of cases the notion that male and female mtDNAs don't recombine
imply that the mtDNA sequence can only be altered by accumulating
mutations along the lineage.
3. mtDNA maintenance
mtDNA is maintained by securing a sufficiently high number of
healthy copies (a phenomenon termed “homoplasmy”, see below in this
section), rather than proofreading a single copy; this is because mi-
tochondria harbor only one DNA polymerase as opposed in the nucleus.
This, and in addition to the fact that DNA in mitochondria are devoid of
protective histones while being in proximity to reactive oxygen species
emanating from the electron transport chain, substantiate the reasons
why mtDNA is ~10 times more prone to uncorrected mutagenesis. It is
not the subject of the present work to review mtDNA maintenance
mechanisms, though some background is hereby outlined so as to assist
the reader, focusing on processes that are associated with neurometa-
bolic diseases. mtDNA maintenance mechanisms are exhaustively re-
viewed elsewhere (Gustafsson et al., 2016), (Suomalainen and
Battersby, 2018), (El-Hattab et al., 2017), (Viscomi and Zeviani, 2017).
Pathways known to be directly involved in mtDNA maintenance are
shown in Fig. 1 (reproduced by permission from (El-Hattab et al.,
2017)). From this figure it is apparent that mtDNA maintenance
Fig. 1. Obtained from (El-Hattab et al., 2017), by permission. A diagram
showing the proteins that are involved in mtDNA maintenance and known to be
associated with MDMDs: 1) Enzymes of mitochondrial nucleotide salvage
pathway that convert the deoxyribonucleosides (thymidine, deoxycytidine,
deoxyguanosine, and deoxyadenosine) to deoxyribonucleotide monopho-
sphates (dNMPs: thymidine monophosphate (TMP), deoxycytidine monopho-
sphate (dCMP), deoxyguanosine monophosphate (dGMP), and deoxyadenosine
monophosphate (dAMP)), then to deoxyribonucleotide diphosphates (dNDPs:
thymidine diphosphate (TDP), deoxycytidine diphosphate (dCDP), deox-
yguanosine diphosphate (dGDP), and deoxyadenosine diphosphate (dADP)),
then to deoxyribonucleotide triphosphates (dNTPs: thymidine triphosphate
(TTP), deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate
(dGTP), and deoxyadenosine triphosphate (dATP)). Thymidine kinase 2 (TK2;
encoded by TK2) and deoxyguanosine kinase (DGK; encoded by DGUOK)
convert the deoxyribonucleosides to dNMPs. Nucleotide monophosphate kinase
(NMPK) converts dNMPs to dDMPs. Nucleotide diphosphate kinase (NDPK)
converts dNMPs to dNTPs. NDPK forms complex with both succinyl-CoA ligase
(SUCL composed of an alpha subunit encoded by SUCLG1 and a beta subunit
encoded by either SUCLA2 or SUCLG2) and gamma-aminobutyrate transami-
nase (GABAT; encoded by ABAT). 2) Enzymes of cytosolic nucleotide metabo-
lism: ribonucleotide reductase (RNR; composed of 2 catalytic subunits and two
small subunits either R2 or p53-inducible small RNR subunit (p53R2; encoded
by RRM2B)) converts ribonucleotide diphosphates (NDPs) to dNDPs. Thymi-
dine phosphorylase (TP; encoded by TYMP) converts thymidine to thymine. 3)
Proteins involved in mitochondrial nucleotide transport: adenine nucleotide
translocator 1 (ANT1; encoded by SLC25A4), acylglycerol kinase (AGK; en-
coded by AGK), and MPV17 protein (encoded by MPV17). 4) Enzymes involved
in mtDNA synthesis: Twinkle (encoded by TWNK) which is a DNA helicase that
separates the DNA stands (presented as blue lines), DNA polymerase γ (pol γ;
consisting of catalytic subunit encoded by POLG and two accessory subunits
encoded by POLG2) which needs RNA primer (presented as red lines) to initiate
DNA synthesis (presented as blue arrows), and mitochondrial transcription
factor A (TFAM; encoded by TFAM) that is required for the generation RNA
primer (presented as red lines). 5) Nucleases removing RNA primers and flap
intermediate (presented as red and blue lines): RNase H1 (encoded by
RNASEH1), DNA helicase/nuclease 2 (DNA2; encoded by DNA2), and mi-
tochondrial genome maintenance exonuclease 1 (MGME1; encoded by
MGME1). 6) Proteins involved in mitochondrial fusion: mitofusin 1 (MFN1;
encoded by MFN1), mitofusin 2 (MFN2; encoded by MFN1), dynamin-related
GTPase OPA1 (encoded by OPA1), and F-box and leucine-rich repeat 4 (FBXL4;
encoded by FBXL4). (For interpretation of the references to colour in this figure
legend, the reader is referred to the Web version of this article.)
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depends on many nuclear gene-encoded proteins. Furthermore, unin-
terrupted provision of nucleotides -achieved by intramitochondrial re-
cycling as well as import from the cytosol-is required. In addition,
mtDNA maintenance also depends on regulated exchange of in-
tramitochondrial contents through mitochondrial fission/fusion and
bioenergetic parameters that affect protein or other metabolite import,
critical for mtDNA. Perturbations in one or more of the above me-
chanisms may impact mtDNA by conferring depletion or large fragment
deletions. In rarer circumstances an excess of mtDNA can be observed
to lead to disease, see section 4.
4. Mitochondrial DNA maintenance defects (MDMDs)
Defects in mtDNA maintenance are due to mutations in nuclear
genes coding for proteins involved in mtDNA synthesis, nucleotide pool
maintenance, mitochondrial fission/fusion or regulating basic bioe-
nergetic processes, rendering them among the most common of the
inherited disorders of metabolism, reviewed in (Schaefer et al., 2004).
Originally reported in 1988 (Holt et al., 1988) and (Wallace et al.,
1988) and considered rare, we now know that the prevalence of mi-
tochondrial diseases can be as high as 1 in 2,000 individuals
(Suomalainen and Battersby, 2018). Secondary causes of mtDNA de-
pletion are reviewed in (Nogueira et al., 2014), (Niyazov et al., 2016),
(Rotig and Poulton, 2009).
The mechanisms by which mtDNA gets depleted are incompletely
understood: until recently, two theories have been formulated, i) the
“slipped-strand model” (Shoffner et al., 1989) a consequence of the
guanine-cytosine bias of the heavy and light strand, and ii) a second
model proposing that deletions are caused by double strand breaks
followed by DNA repair (Krishnan et al., 2008). Most recently though,
evidence was put forward suggesting that mtDNA deletions are formed
by copy-choice recombination during active DNA synthesis of the light
strand (Persson et al., 2019), arguing against both previously proposed
models.
mtDNA depletion can also be drug-induced (Arnaudo et al., 1991),
as it occurs during anti-retroviral treatment (Montaner et al., 2004),
(Casula et al., 2007), (Morse et al., 2012), (Lewis et al., 2003), (Young,
2017). One-fifth of patients undergoing anti-retroviral treatment de-
velop a phenotype stemming from mtDNA depletion, although in most
cases this is reversible upon cessation of treatment (Lewis et al., 2003),
(Young, 2017), (Dagan et al., 2002), (Lewis et al., 2001). Whatever the
cause of damaging mtDNA maintenance, the result may be quantitative
(mtDNA depletion) or qualitative (multiple mtDNA deletions). mtDNA
deletion syndromes are caused by large-scale deletions of mtDNA on the
order of several thousand base pairs and are usually sporadic (Holt
et al., 1988). This author supports the classification by El-Hattab,
Craigen and Scaglia, including the concept that defects in mtDNA
maintenance genes result in mtDNA depletion and multiple mtDNA
deletions, both representing the spectrum of a single disease group (El-
Hattab et al., 2017), thus adopting the term of mitochondrial DNA
maintenance defects (MDMDs). Rarely, mtDNA maintenance defects
may be because of an excess: by supplementing HeLa cells with surplus
thymidine for just 4 h, mitochondrial dTTP and dGTP pools increased to
such an extent that multiple mtDNA deletions were apparent after 8
months of culture (Song et al., 2003); furthermore, a very high mtDNA
copy number was associated with several pathologies associated with
mtDNA maintenance defects in transgenic mice (Ylikallio et al., 2010);
in humans, this possibility remains unexplored.
When inherited, MDMDs do so in an autosomal recessive or domi-
nant manner and can basically manifest in any organ at any time
(Suomalainen and Battersby, 2018). Pathogenic variants for all nuclear
genes depicted in Fig. 1 have been reported to yield an MDMD. mtDNA
depletion syndromes are reported and periodically updated in the
OMIM database; currently, the search string ["mtDNA depletion” OR
“mitochondrial DNA depletion"] in OMIM database yields 65 entries.
What is important to realize is that the knowledge of a specific defect in
mtDNA due to one reason or another, does not afford the investigator
with the capacity of predicting the severity of disease, simply because
the latter depends on at least three parameters: i) the severity of mu-
tation, partially dictated by its position in the affected gene, ii) per-
centage of variable mtDNA content, and iii) likelihood for disease
manifestation (phenotype). The latter parameter also depends on the
affected organ; furthermore, with lesser amount of mtDNA, chances for
pathogenic mtDNA depletion increases. Thus, these three parameters
are strongly interrelated.
Despite that MDMDs may appear in any organ at any time, on the
basis of an apparent preponderance for tissue-specific manifestation
these disorders are usually classified as myopathic, encephalomyo-
pathic, hepatocerebral or neurogastrointestinal (El-Hattab and Scaglia,
2013). In most cases it is thought that because adequate amount of
mtDNA is required for the production of subunits of mitochondrial re-
spiratory chain complexes and therefore energy-harnessing through
oxidative phosphorylation (OXPHOS), mtDNA depletion results in en-
ergy-shortage (Moraes et al., 1991), (Sarzi et al., 2007), (Spinazzola
et al., 2009). Notably though, MDMDs leading to respiratory chain
dysfunction let subunits of complex II intact, simply because they are all
nuclear-encoded. However, mindful that mitochondria participate in
calcium homeostasis, biosynthesis of heme and steroid hormones,
apoptosis, cell cycle regulation –to name a few-it must be pointed out
that exactly because they do so many things, it is oversimplifying to
consider that mtDNA depletion –or any mitochondrial problem for that
matter-yields phenotypes exclusively from issues regarding OXPHOS.
Indeed, mitochondria require ~1,500 proteins for proper operation
(Pagliarini et al., 2008), (Calvo and Mootha, 2010) out of only ~100 of
are directly involved in oxidative phosphorylation and the production
of ATP (Gorman et al., 2016). This concept is critical for understanding
the novel diagnostic test outlined below in which mitochondria are
challenged to benefit from glutaminolysis in the absence of an active
respiratory chain, see section 6.
5. Insufficient correlation between mtDNA quantification and
neurometabolic disease severity
When a neurometabolic disease is suspected of having a mi-
tochondrial origin a host of clinical assessments and multitude of in-
vestigations are at hand which differ for pediatric vs adult patients
(Bernier et al., 2002), (Walker et al., 1996). Historically, serum creatine
kinase, alanine and lactate levels have been used as indices of mi-
tochondrial diseases, but these measures are known to be nonspecific
and somewhat insensitive (Debray et al., 2007). Muscle biopsy followed
by histologic and functional assessment are the “gold standard”
(Mitochondrial Medicine Society's Committee on et al., 2008),
(Suomalainen, 2011), (Viscomi and Zeviani, 2017), (Nishigaki et al.,
2003), (Nishino et al., 1999), (Nolden et al., 2005), (Ostergaard et al.,
2007a), (Chretien et al., 1998), however, carrying a number of un-
certainties (Tucker et al., 2011). Functional assays encompass re-
spiratory chain component activities including that of the Fo-F1 ATP
synthase, blue-native gel electrophoresis, semi-quantitation of the var-
ious protein components within complexes and supercomplexes via
western blots and gel electrophoresis, oxygen consumption rate esti-
mations and their alterations in the presence of various specific in-
hibitors. However, a muscle biopsy is invasive, exhibits high false-ne-
gative and false-positive rates and a disappointingly high
irreproducibility among laboratories evaluating respiratory chain en-
zyme activities (Rodenburg et al., 2013), (Medja et al., 2009). In ad-
dition, in muscle homogenate the activity of respiratory chain compo-
nents may vary from normal to about 50% of the controls' mean
(Servidei et al., 1991). Despite that MDMDs were discovered by mea-
suring enzymatic activities of the respiratory chain complexes in af-
fected tissues based on measurements prone to inaccuracies, exactly
because of the complexity and high degree of irreproducibility, Viscomi
and Zeviani have tactfully suggested that “these assays should be
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carried out in specialized centers, as they require ad hoc expertise and
standardized, verified and complex technologies and diagnostic proto-
cols” (Viscomi and Zeviani, 2017). Finally, the costs of surgical proce-
dures especially for children are considerable, since they require an-
esthesia (Suomalainen, 2011). On the other hand, new biomarkers
show promise in diagnosing mitochondrial diseases, such as measuring
the serum levels of fibroblast growth factor 21 (FGF21) and growth/
differentiation factor 15 (GDF15) (Suomalainen et al., 2011), (Davis
et al., 2013), (Yatsuga et al., 2015).
Mindful that normal respiratory chain activities in muscle do not
exclude respiratory chain deficiency in another tissue, an under-
appreciated factor for diagnosis of mitochondrial diseases is tissue se-
lection. As stated above, the amount of depleted mtDNA may vary
among cells and therefore within and between tissues. In general, tis-
sues harboring the highest levels of mtDNA depletion tend to be those
that are difficult or almost impossible to obtain such as the brain, heart,
retina and cochlea whereas more accessible tissues such as skin fibro-
blasts and blood cells exhibit low mutation levels (Sue et al., 1998). It is
considered prudent to culture fibroblasts obtained from a skin biopsy
from a patient who donated muscle for diagnostic procedures under the
impression that fibroblasts may harbor the deficiency in oxidative
phosphorylation as shown in skeletal muscle and serving as a much
easier tissue for diagnostic workup regarding assigning pathogenicity to
new mutations (Gorman et al., 2016). This may assist in the following:
once an index case has been identified, relatives can also be tested in a
much less invasive manner by providing buccal, urine and blood DNA
samples (Gorman et al., 2016). However, reports of classical MDMDs
are outlined below in which mtDNA was not found to be depleted in
several tissues. In almost all cases, mtDNA was quantified by Southern-
blot analysis or real-time PCR (Gourlain et al., 2003). In both ap-
proaches, mtDNA amount is compared to a specific nuclear reference
gene, and always examined using age- and tissue-matched controls as
well (Clay Montier et al., 2009), (Hakonen et al., 2007), (Gotz et al.,
2008). An extent of mtDNA decrease of more than 35–40% compared to
controls is deemed pathologic (Poulton and Holt, 2009).
In (Tzoulis et al., 2014) it was shown that autosomal recessive
mutations in POLG (see also Fig. 1) mtDNA depletion and secondary
mtDNA mutations were cell- and tissue-specific. In (Nishino et al.,
1999) and (Nishino et al., 2000), only half of the patients exhibiting
mutations in TP causing mitochondrial neurogastrointestinal en-
cephalomyopathy (MNGIE) syndrome harbored mtDNA depletions. In
patients with deoxyguanosine kinase (DGUOK) mutations, mtDNA de-
pletion was observed in liver but not in muscle (Mandel et al., 2001),
even though this disease affects the muscle as well (Freisinger et al.,
2006). The effect of DGUOK mutations on mtDNA content obtained
from fibroblasts is variable (Morten et al., 2007). In (Gauthier-Villars
et al., 2001), it was shown that patients suffering from Alpers-Hutten-
locher syndrome usually exhibit respiratory chain defects and mtDNA
depletion in liver, but not always in skeletal muscle; fibroblasts were
shown to be mosaic in nature in respect of their mtDNA content. Fi-
nally, mtDNA depletion was found to be brain-specific in patients with
infantile-onset spinocerebellar ataxia (IOSCA) syndrome while no al-
terations were found in muscle (Hakonen et al., 2008). In (Ostergaard,
2008), it was shown that in patients with mutations in SUCLG1 and
SUCLA2 a combined respiratory chain defect was observed in liver or
muscle, but not in skin fibroblasts. Likewise, in muscle of SUCLA2-de-
ficient individuals mtDNA content was reduced to 20–60% compared to
age-matched controls (Elpeleg et al., 2005), (Carrozzo et al., 2007),
(Ostergaard et al., 2007b), (Carrozzo et al., 2016). In patients suffering
from TK2 deficiency, only 66% of those exhibited a greater than 30%
mtDNA depletion (Garone et al., 2018).
In the same line of thought, i.e. that mtDNA depletion may not be
necessarily leading to mitochondrial pathology in humans, the
MPV17−/− mouse with severe mtDNA depletion in liver failed to de-
monstrate an appreciable decrease in respiratory chain activities, not
even overt liver failure with age, only grey hair early in adulthood and
focal segmental glomerulosclerosis with massive proteinuria and co-
chlear lesions (Viscomi et al., 2009).
Overall, mtDNA depletion in a tissue does not imply depletion in
another; by the same token, mtDNA depletion is not necessarily asso-
ciated with respiratory chain defects.
6. Mitochondrial substrate-level phosphorylation (mSLP) in the
absence of electron transport and its use as a mitochondrial
diagnostic marker
It has been firmly established that when the respiratory chain is
pharmacologically inhibited or in the presence of anoxia, mitochondria
are still able to utilize downstream metabolites of glutamine (gluta-
mate, α-ketoglutarate) using NAD+ obtained from sources other than
complex I (Chinopoulos, 2019), (Ravasz et al., 2018), (Kiss et al., 2013),
(Chinopoulos et al., 2010), a concept which is likely to be exploited in
cancer cells thriving in adverse tumor microenvironments (Chinopoulos
and Seyfried, 2018). This serves the purpose of generating high-energy
phosphate nucleotides within the mitochondrial matrix through the
process of mitochondrial substrate-level phosphorylation (mSLP) for i)
fueling a reverse-operating F0–F1 ATP synthase (Chinopoulos, 2011b)
and ii) maintaining the ANT in forward mode, thus un-straining gly-
colysis (Chinopoulos, 2011a). An mSLP test is qualitative (presence vs
absence of mSLP, there is no parameter that needs to be quantified) and
can be performed in skin fibroblasts requiring no specialized machinery
(spectrofluorimetry in plate or cuvette format is standard laboratory
equipment). The test that we have devised is based on an “interroga-
tion” of the directionality of succinate-CoA ligase (SUCL), a citric acid
cycle enzyme that interconverts succinyl-CoA and ADP (or GDP) to
CoASH, succinate and ATP (or GTP) (Johnson et al., 1998), essentially
performing mSLP. This enzyme is a heterodimer composed of an in-
variant α subunit encoded by SUCLG1 and a substrate-specific β sub-
unit, encoded by either SUCLA2 or SUCLG2. This dimer combination
results in either an ATP-forming (EC 6.2.1.5) or a GTP-forming SUCL
(EC 6.2.1.4). The possibility of co-presence of an ATP- and GTP-forming
SUCL in the same mitochondrion has only been recently investigated in
human fibroblasts, where it was found that in these cells the majority of
in situ mitochondria co-express both isoforms (Chinopoulos et al.,
2019), see Fig. 2 (reproduced from (Chinopoulos et al., 2019) by per-
mission). This seems redundant, mindful that an intramitochondrial
diphosphate kinase (NME4) can transfer the high-energy bond between
adenine and guanine nucleotides (Lacombe et al., 2018). In any case,
mSLP supports the production of sufficient amounts of [ATP] in the
mitochondrial matrix for both a reverse-operating F0–F1 ATP synthase
(Chinopoulos, 2011b) and maintain the ANT in forward mode
(Chinopoulos, 2011a). Presence of mSLP maintains ANT in forward
mode for reasons outlined in (Chinopoulos, 2019), (Ravasz et al.,
2018), (Kiss et al., 2013), (Chinopoulos et al., 2010), and this can be
easily assessed by checking the effect of a highly-specific ANT inhibitor
–carboxyatractyloside- in permeabilized cells with blocked complex I
(using rotenone). Under these conditions, mSLP can only occur in the
presence of suitable substrates specifically those stemming from glu-
taminolysis, but not succinate (Kiss et al., 2013). Such a test is depicted
in Fig. 3 (obtained from (Tretter et al., 2016), by permission). As shown
in figure panel 3A, the test relies on the principle that the ATP-ADP
exchange through the ANT is electrogenic, since one molecule of ATP4
− is exchanged for one molecule of ADP3 − (Klingenberg, 2008). If the
ANT operates in forward mode, abolition of its operation by carbox-
yatractyloside (cATR) will lead to a gain of ΔΨm. If the ANT operates in
reverse, abolition of its operation by the inhibitor will lead to a loss of
ΔΨm. Note that addition of the ANT inhibitor must take place after
complex I is inhibited (i.e. by rotenone), thus, it cannot be over-
emphasized that the mSLP test addresses the extent of compensation
(i.e. remaining mitochondrial functionality) when the electron trans-
port chain is non-functional. It does not yield any information regarding
the respiratory chain, it only provides information if the in situ
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mitochondria of the examined cells are able to harness energy from
glutamine-derived metabolites when the respiratory chain is inhibited.
In essence, this test will hint on the ability of mitochondria to cope with
a defect in their respiratory chain. By employing this test, we have
reported that defects in SUCLA2 and SUCLG1, respectively, yield an
mSLP negative test, i.e. no mSLP present. As shown in figure panels 3B
and 3C, in situ fibroblast mitochondria of a SUCLA2-deficient patient
(B) or SUCLG1-deficient patient (C) exhibited no mSLP compared to
age-matched controls. Note that patients with defects in SUCLA2 and
SUCLG1 exhibit mtDNA depletion in some but not all tissues, while the
phenotypes are debilitating leading to life termination at a young age
(Ostergaard, 2008). Obviously, this test has been applied in fibroblasts
from patients suffering from MDMDs due to mutations in the enzyme
directly related to mSLP; efforts are ongoing in our laboratory to verify
the validity of this test using fibroblasts from patients suffering from
various mtDNA depletion syndromes.
Finally, it may be relevant to ponder on the fact that mSLP relies on
a sufficient clearance of succinate, which can occur by increasing suc-
cinate dehydrogenase (SDH) activity; it is thus not surprising that in
several MDMDs, ragged-blue fibers are observed in histological ex-
amination of muscle tissue, which is none other than an increase in SDH
activity (DiMauro et al., 1999).
6.1. mSLP protocol
The mSLP protocol can be performed in cultured fibroblasts exactly
as in (Kacso et al., 2016) and (Chinopoulos et al., 2019). It is best to
compare cultured fibroblasts from the patient and at least three con-
trols. It is not important to age- and gender-match the controls to the
patient; the controls serve the purpose of ensuring that the mSLP pro-
tocol is being performed correctly; it is not a quantitative test, and for
this reason it is also not necessary to normalize results to protein con-
tent or a housekeeping protein. Basically, fibroblasts [two 75 cm^2
(midi) or one 175 cm^2 (maxi) flask)] are cultured to approximately
80% confluence. On the day of the experiment, two buffers need to be
prepared: 500ml of ice-cold buffer “A”, containing 110mMK-gluco-
nate, 10mM HEPES (free acid), 10mM KH2PO4, 10mM mannitol,
10mM NaCl, 8 mM KCl, 1.5mMMgCl2, 0.01mM EGTA, 0.5 mg/ml BSA
(essentially fatty acid-free), with the pH adjusted to 7.25 with KOH, and
5ml of buffer “B” which in addition to the substances mentioned for
buffer “A” it contains the following: 5 μM safranine O, 5mM glutamate,
5 mM malate, 5 mM α-ketoglutarate and 175 μl of 2.5 mM digitonin
(purity > 90%, dissolved in DMSO). For exact catalogue numbers of
chemicals, the reader is referred to http://antactivity.com/Buffers_
chemicals.html. Buffer “B” must be kept at 37 °C. Feeding media are
aspirated and cells are washed once with ice-cold buffer “A”, then
harvested by scraping in buffer “A” (no need for trypsinization, cells
will be eventually permeabilized for the mSLP assay within a few
Fig. 2. Confocal images of immunolabeling of human fibroblasts from healthy subjects. Blue: anti-SUCLA2; Red: anti-SUCLG2; Green: Mitotracker orange (MTO).
Reproduced from (Chinopoulos et al., 2019) by permission. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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minutes, it is redundant to maintain high viability of the cells). Pellet
cells by centrifugation at 3,500 rpm for 2.5 min using an angular rotor
(or at 1,100 rpm for 10min if a swing-bucket rotor is used) in at 50ml
tubes containing at least 40ml of buffer (to dilute calcium of the
feeding media as much as possible). Wash cells once with buffer “A”,
and repeat the centrifugation step. Resuspend final pellet in 0.7 ml of
buffer “B”. Use a plate reader for recording safranine O fluorescence
(495ex/585em). Split the 0.7ml pellet in three 0.2ml (record in tri-
plicates) and add to individual wells of a 96 white plate suitable for
fluorescence, and insert into the plate reader. The interior of the plate
reader must be kept at 37 °C; possibility for automatic shaking of the
plate is imperative (i.e. every 3 s). Acquisitions should be made every
10–15 s. Allow 5min for adequate polarization of in situ mitochondria
and cell membrane permeabilization by digitonin. Record baseline for
3min, add 2mM ADP (from a 6.9 pH-ed 200mM stock, see http://
antactivity.com/Buffers_chemicals.html), see Fig. 3. Record for 3 more
minutes, then add 5 μM rotenone. Record for an additional 3min, then
add 1 μM carboxyatractyloside. Record for an additional 3min, then
add 250 nM of the uncoupler SF6847. The volume of each addition to
each well should be not less than 1 μl and no more than 2 μl. Convert
fluorescence traces to percentages and compare the 3 controls with that
from the patient cells. If carboxyatractyloside leads to hyperpolariza-
tion in the controls but to a depolarization in the patient, mSLP in the
patient is impaired. This means that the fibroblasts of the patient are
unable to harness ATP from mitochondrial substrate-level phosphor-
ylation from glutaminolysis, thus his/her mitochondria cannot com-
pensate for a potential electron transport chain dysfunction to an ap-
preciable degree.
7. Conclusions
The present review does not make an attempt to indicate how much
mtDNA depletion is required for disease manifestation; it merely dis-
cusses that quantitating mtDNA on peripheral –but not limited to-tis-
sues is not pathognomonic. Furthermore, the concept of mSLP as a
qualitative and not quantitative test for evaluating the extent of mi-
tochondrial functionality in the absence of an electron transport chain
is put forward. Having said that, it cannot be overemphasized that the
mSLP test cannot be used to differentiate among the numerous defects
described in mtDNA translation, or involving a single complex, or
secondary to other diseases involving mitochondrial dysfunction; it can
only provide an indication if the affected mitochondria are able to
energetically compensate and maintain –albeit- minor- ATP production
and not act as sinks of cytosolically made ATP.
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